Ketamine and Esketamine in Residential Mental Health for Treatment-Resistant Depression

, ,
Nurse securing an IV catheter in a patient during a monitored ketamine infusion in a residential mental health setting

For a person whose depression has not responded to two or more adequate trials of standard antidepressants, the treatment options that remain are meaningfully different from the standard first-line playbook. Ketamine and its FDA-approved cousin esketamine (Spravato) have moved from experimental to mainstream over the past decade, and integrating them into a residential mental health stay is now one of the most effective ways to shorten the arc from acute suicidal depression to stable remission. At Bodhi Mental Health, we build ketamine and esketamine protocols into residential care for patients whose depression has resisted the standard sequence.

This article covers how ketamine and esketamine differ, the evidence supporting their use in treatment-resistant depression, why the residential setting is often the right place to initiate treatment, how we sequence infusions or intranasal dosing with psychotherapy, and the safety monitoring that has to happen alongside every dose.

How Ketamine and Esketamine Differ

Ketamine is a racemic anesthetic that has been in medical use for decades and is administered off-label for depression, typically by intravenous infusion at sub-anesthetic doses. Esketamine is the S-enantiomer of ketamine, formulated as an intranasal spray and FDA-approved specifically for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. The FDA approved Spravato in 2019 under a Risk Evaluation and Mitigation Strategy that requires administration in a certified healthcare setting.

Both act primarily on NMDA glutamate receptors, a different mechanism than the monoamine reuptake pathway of standard antidepressants. This is why they often work in patients who have failed multiple SSRIs and SNRIs, and why response can occur within hours to days rather than the four to six weeks typical of standard antidepressants. The National Institute of Mental Health summarizes the current evidence base for both agents.

Why the Residential Setting Is Often the Right Place to Start

Initiating ketamine or esketamine treatment requires close clinical monitoring for the first few doses because dissociative side effects and transient blood pressure elevations are common in the two hours immediately after administration. In an outpatient model, patients drive to a clinic, receive the dose, are observed for two hours, and are then discharged home, often to arrange their own follow-up. In a residential setting, the same patient stays on-site with twenty-four-hour clinical support, which matters most for patients who are severely depressed or actively suicidal.

The residential setting also makes it possible to integrate the medication with intensive daily therapy in a way that outpatient dosing cannot. A patient can receive an esketamine dose in the morning and process the emerging cognitive shifts in individual therapy that afternoon, and again in group therapy the next day. Read our companion article on TMS therapy in residential mental health treatment-resistant depression for how we sequence other neuromodulation options.

The Evidence Base for Treatment-Resistant Depression

The pivotal esketamine trials showed statistically significant improvement in depression rating scales compared with placebo when added to a newly initiated oral antidepressant, and durability studies have shown that maintenance dosing extends remission. Racemic IV ketamine has a larger clinical experience base though a smaller regulatory footprint, and the two are often used interchangeably in clinical practice depending on formulary, insurance coverage, and patient preference.

For patients with major depressive disorder and acute suicidal ideation, the specific indication esketamine holds, the evidence is particularly strong that the medication can reduce suicidal ideation within twenty-four hours in a way no other antidepressant can match. The 988 Suicide and Crisis Lifeline is always the first resource for anyone in acute crisis; residential ketamine or esketamine care is one of the higher-acuity treatment options once a patient is medically stable. See our overview on when severe symptoms warrant residential treatment.

How We Sequence Ketamine or Esketamine with Psychotherapy

The typical Spravato induction is twice-weekly dosing for four weeks, then weekly for four weeks, then every one to two weeks for maintenance. IV ketamine protocols vary but often use a series of six infusions over two to three weeks during acute treatment. In our residential program, the medication schedule is timed to align with a structured therapy calendar that includes daily individual sessions, DBT skills groups, and specific integration sessions to make use of the neuroplasticity window that follows dosing.

Ketamine and esketamine appear to open a period of increased neuroplasticity in the hours to days after a dose, during which the brain may be more responsive to therapy. We time cognitive and processing work to that window rather than to arbitrary calendar slots. See our related post on GeneSight vs Genomind for treatment-resistant depression for how pharmacogenomic testing can inform which oral antidepressant we pair with esketamine.

Safety Monitoring and Contraindications

Blood pressure is measured before dosing and at forty and ninety minutes after. Dissociation is expected in the first two hours and typically resolves without intervention. Nausea, dizziness, and sedation are also common. Patients cannot drive for the remainder of the day after any dose, which is another argument for the residential setting during induction. Contraindications include uncontrolled hypertension, active psychosis, and a history of aneurysmal vascular disease.

Ongoing monitoring throughout treatment includes standardized depression and suicidality scales, side effect tracking, and coordination with the outpatient psychiatrist who will manage maintenance dosing after discharge. Our related post on DBT in residential mental health treatment covers one of the therapy modalities we most often pair with ketamine or esketamine dosing.

Getting Started at Bodhi Mental Health

If depression has not responded to two or more antidepressants at adequate dose and duration, or if suicidal ideation is present, a residential mental health stay with integrated ketamine or esketamine can be a meaningful option worth discussing. Our admissions team can complete a clinical assessment by phone and verify PPO insurance benefits typically within an hour.

Call Bodhi Mental Health at 877-883-0780 to speak with an admissions counselor today, or visit our admissions page to begin the process online.

/by

Internal Family Systems (IFS) Therapy in Residential Mental Health Treatment for Complex Trauma and Depression

, ,
Psychiatrist reviewing an Internal Family Systems treatment plan with a client during a residential mental health program consultation

Internal Family Systems (IFS) therapy has become one of the most widely requested modalities in residential mental health treatment for adults navigating complex trauma, severe depression, and post-traumatic stress. Developed by Richard Schwartz in the 1980s and formally recognized by the SAMHSA National Registry of Evidence-Based Programs and Practices, IFS is neither a coping-skills class nor a talk-therapy add-on. It is a structured, relational approach that changes how a person relates to their own internal experience — and, in residential settings, it produces measurable shifts within weeks rather than years.

At Bodhi Mental Health in Northern California, IFS is offered as part of a comprehensive residential program that integrates neuromodulation, pharmacogenomic-guided medication, and evidence-based psychotherapy. This guide explains what IFS is, why residential intensity matters for trauma work, and how the therapy fits into a typical 30- to 60-day admission.

What Internal Family Systems Therapy Actually Is

The core premise of IFS is that the mind is naturally multiple. Rather than viewing the psyche as a single unified voice, IFS holds that everyone contains a system of distinct parts — a critical inner voice, a wounded younger self, a protector that shuts down when overwhelmed, a numbing part that reaches for food or alcohol, and so on — organized around a core Self that is calm, curious, and compassionate.

Trauma disrupts that system. Parts that developed to protect the child become rigid and extreme in the adult. A person who learned to disappear during a chaotic childhood may find that a “numbing” part hijacks their nervous system whenever conflict arises, even decades later. IFS therapy does not try to eliminate those parts. Instead, the therapist helps the client access Self and, from that centered place, form a new relationship with the parts — hearing what they are protecting, thanking them, and gently updating them.

The National Institute of Mental Health (NIMH) recognizes trauma-focused psychotherapies including IFS-adjacent modalities as first-line for complex PTSD, and randomized controlled trial evidence supports IFS for adults with PTSD symptoms following childhood abuse.

Why IFS Belongs in a Residential Program

IFS work is powerful and can be destabilizing between sessions, especially for clients with complex trauma or active suicidality. In outpatient therapy at 50 minutes a week, a client who accesses a deeply protected part in session may spend the following six days flooded with emotion, without the clinical support to metabolize it. Residential settings solve that problem structurally.

Inside a residential program, IFS therapy is layered into a full day of stabilization: individual sessions two to three times per week, daily group therapy, medication management, and 24/7 clinical availability. Clients doing hard trauma work in the morning have access to a nurse, a therapist, and a milieu of peers doing the same work by afternoon. That containment is what makes IFS accessible to people who could not safely do the work at any lower level of care. See our post on when outpatient therapy isn’t enough for a broader discussion of clinical thresholds.

What an IFS Session Looks Like in Residential Treatment

A typical IFS session begins with the client and therapist identifying a part that feels prominent — often the one running the show during a recent difficult moment. The therapist asks the client to notice where they feel that part in their body, then to check how they feel toward it. If the client reports irritation, fear, or judgment, those are other parts also present. The therapist gently asks those parts to step back so the client can meet the target part from Self.

From Self, the client asks the part what it wants them to know. In residential settings — where the client has slept eight hours, taken their medication, and has no immediate life stressors — this dialogue often surfaces material that would take months to access in outpatient care. The therapist tracks the system, notes protective dynamics, and helps the client update parts that are still living inside old trauma.

Between sessions, clients often continue the work through parts journaling, guided IFS meditations, and structured processing groups. Sessions integrate naturally with modalities like brainspotting and DBT, which many residential programs sequence alongside IFS depending on the client’s clinical profile.

Speak with a Bodhi Mental Health admissions clinician.

Our Northern California team is available seven days a week to verify insurance, review clinical needs, and coordinate admission. Call 877-883-0780 or start a confidential application online.

Who Is a Good Candidate for IFS in Residential Care

IFS works particularly well for adults with:

  • Complex trauma or childhood abuse histories that have not responded fully to outpatient therapy
  • Treatment-resistant depression with a strong self-critical or self-loathing internal voice
  • Chronic dissociation, emotional numbing, or a sense of feeling “split” internally
  • Co-occurring eating disorders, self-harm, or substance-use behaviors that the client experiences as being driven by “a part of me”
  • Perfectionism and high-functioning depression that has become unsustainable

IFS is not the right first modality for every client. People in acute psychosis or severe mania need stabilization with medication and structure before trauma work. Clients with active suicidal intent typically start with safety planning and DBT skills before entering deep IFS territory. Our admissions team screens for these considerations before every intake.

How IFS Fits With Medication, TMS, and Other Modalities

A residential admission is rarely single-modality. IFS is most powerful when combined with the right medication regimen and, for treatment-resistant clients, neuromodulation. Clients whose depression has not responded to multiple medication trials often receive TMS therapy alongside psychotherapy, and GeneSight pharmacogenomic testing helps our psychiatrists select medications that the client’s metabolism can tolerate.

For clients with severe PTSD who need trauma-processing before IFS parts work becomes accessible, we may sequence a phase of stabilization and skills-building first. See our related posts on residential treatment for severe PTSD and complex trauma and residential care.

Start Residential Mental Health Treatment in Northern California

If outpatient therapy has not moved the needle on complex trauma, depression, or dissociation, an integrated residential program that includes IFS may be the next step. Bodhi Mental Health provides that intensity in a private, low-census Northern California setting.

Call our admissions clinicians at 877-883-0780 or verify your insurance benefits online. Confidential consultations available seven days a week.

/by

How Does GeneSight Testing Guide Medication in Residential Mental Health Treatment?

,
How Does GeneSight Testing Guide Medication in Residential M

How GeneSight pharmacogenomic testing guides medication in residential mental health treatment - peaceful sunlit forest sanctuary

For someone entering residential care with treatment-resistant depression, severe anxiety, or bipolar disorder, the medication trial-and-error process can feel demoralizing after months or years of switching prescriptions with limited response. This is where pharmacogenomic testing changes the conversation. Understanding how GeneSight testing guides medication in residential mental health treatment can shorten the window between admission and meaningful stabilization — because clinicians work from the individual’s genetic metabolism data rather than population averages. At Bodhi Mental Health, this personalized approach fits into a structured residential program designed for severe conditions that outpatient care could not reach.

Why Pharmacogenomic Testing Matters Inside a Residential Program

Standard psychiatric prescribing follows algorithms based on population studies — first-line SSRI, then a switch, then augmentation, then a class change. For patients whose symptoms are severe enough to require residential care, that timeline is not clinically acceptable. Pharmacogenomic testing (branded products include GeneSight, Genomind, and others) analyzes cytochrome P450 enzyme genes such as CYP2D6, CYP2C19, and CYP3A4 to predict how quickly or slowly the patient metabolizes specific psychiatric medications. The report categorizes each drug into use-as-directed, use-with-caution, or significant-gene-drug-interaction tiers.

Inside a residential setting, these results become actionable within days rather than months. Our psychiatric team can adjust dosing, avoid classes likely to fail, and confidently trial medications that outpatient providers may have dismissed. For treatment-resistant conditions, that speed is what makes residential care worth the disruption.

Who Benefits Most from GeneSight Testing in Residential Mental Health Treatment

Not every resident needs pharmacogenomic testing on day one, but certain profiles benefit dramatically:

  • Adults with treatment-resistant depression who have tried three or more antidepressants without adequate response.
  • People with severe anxiety or panic disorder who report unusual side effects on standard doses.
  • Individuals with bipolar disorder navigating mood stabilizer choices where the wrong medication could precipitate a mood episode.
  • PTSD or complex trauma patients whose SSRIs have failed or caused activation.
  • Anyone with a family history suggesting atypical medication metabolism — for example, a parent who “never tolerated antidepressants.”

How the Testing Fits Into a Residential Timeline

A pharmacogenomic test is a cheek swab. Results typically return within three to five business days. Because a residential stay at Bodhi runs longer than an outpatient visit, we can complete the swab early in admission, review results with our psychiatric team, and integrate them into the treatment plan before the second week begins. That means medication changes are informed by genetic data by the time the resident is deep in therapy work — brainspotting for PTSD, EMDR for trauma, group therapy for depression — and less likely to be derailed by a poorly tolerated prescription.

Learn more about how medication management integrates with our treatment programs and the intensive structure of our residential mental health program.

What Pharmacogenomic Testing Does Not Do

Pharmacogenomic testing is a tool, not a diagnosis. It does not tell the psychiatrist which medication will work — it tells them how the patient will likely metabolize candidates. A genetic report showing that a specific SSRI is “use with caution” does not mean the drug will fail; it means the dose may need adjustment or that side effect vigilance is warranted. Clinical judgment, symptom tracking, and therapeutic relationship still drive prescribing decisions inside residential care. The genetic data simply removes some of the guesswork from a process that has historically been slow and frustrating for patients with severe conditions.

Combining GeneSight Results with Other Interventions

For residents whose depression has resisted multiple medication trials, pharmacogenomic testing often pairs with other advanced interventions. This may include TMS (transcranial magnetic stimulation) referrals, neurofeedback sessions, or ketamine-assisted psychiatric consultations depending on clinical picture. Our team also considers pharmacogenomic data when planning the medication regimen a resident will continue after discharge — including during any step-down to our in-network virtual IOP or an outpatient program back home.

Insurance, Cost, and Practical Considerations

Most major commercial insurance plans cover GeneSight or comparable testing when medical necessity is documented — which is typically straightforward for someone entering residential mental health treatment after multiple failed outpatient medication trials. Our admissions team can help verify insurance and outline what will be covered before you arrive. For families weighing whether residential care is worth the investment, the ability to compress months of medication trial-and-error into a single, structured stay is a significant part of the answer.

When to Consider a Residential Mental Health Program

Pharmacogenomic testing is powerful, but it does not replace the level-of-care decision. If someone is safe at home and mildly symptomatic, they may not need residential treatment. If depression, anxiety, PTSD, or bipolar symptoms have escalated to the point where daily functioning has collapsed or safety is a concern, residential care provides the containment, medical oversight, and therapeutic intensity that outpatient work cannot. Our facility tour and confidential admissions conversations help families understand whether Bodhi is the right fit. Privacy matters, especially for professionals whose careers depend on confidentiality during a mental health leave.

Ready to Talk About Residential Care?

If treatment-resistant depression, severe anxiety, PTSD, or bipolar symptoms are pushing you or a loved one past what outpatient care can handle, we’re here to walk you through what admission looks like — including how GeneSight testing fits in. Call 877-883-0780 or apply now for a confidential conversation with our admissions team.

/by

Treatment-Resistant Depression: When Residential Mental Health Treatment Is the Right Next Step

,
Quiet evening room with warm light, representing the calm structured environment of residential mental health care for treatment-resistant depression

Table of Contents

Among the people who do everything right with depression treatment — the weekly therapy, the antidepressants tried in sequence, the lifestyle changes recommended by the psychiatrist — there’s a subset for whom the standard outpatient model doesn’t produce the change it’s supposed to. The clinical term is treatment-resistant depression. The lived experience is something more like: “I’m doing all of it and I’m still not getting better, and I don’t know what to do next.”

If that’s familiar, the next step worth considering isn’t another medication trial or another six months of weekly outpatient. It’s often a different level of care entirely. Below is a practical look at what treatment-resistant depression actually means clinically, why residential mental health treatment can break the pattern when outpatient hasn’t, and how to know whether residential is the right next step. If you’d like to talk through your situation, our team is reachable at 877-883-0780.

What “Treatment-Resistant” Actually Means

Clinically, treatment-resistant depression typically refers to depression that hasn’t responded adequately to two or more antidepressant trials at therapeutic doses for an adequate duration (generally 6–8 weeks per trial). For many specialists, the criteria also include a course of evidence-based psychotherapy (CBT or interpersonal therapy) of adequate duration without sufficient response.

By those definitions, treatment-resistant depression is not rare. Roughly one in three people with major depressive disorder will meet treatment-resistance criteria at some point in their illness. The number is higher when you include people who get partial response but never reach remission — the “I’m functioning but I’m not actually well” state that many people live in for years.

Why Outpatient Sometimes Isn’t Enough

Standard outpatient treatment for depression — weekly therapy plus medication management every few weeks — is designed for situations where the structure of the person’s life can absorb the work between sessions. For mild to moderate depression that’s often true. For severe or treatment-resistant depression, several variables work against the outpatient model:

The 167 hours between sessions. A weekly therapy hour is 0.6% of the week. In severe depression, the rest of the time is when most of the difficult work happens — and outpatient doesn’t reach into those hours.

Medication adjustments at outpatient pace. Trying a new medication, waiting 6–8 weeks for response, then adjusting if it didn’t work, means a single medication trial can take 2–3 months. Three failed trials means most of a year. For someone whose functioning is meaningfully impaired, that timeline is too slow.

The home environment as a variable. Daily life with severe depression often includes patterns — isolation, disrupted sleep, eating problems, certain relationship dynamics — that maintain the depression even as treatment tries to interrupt it. Without changing the environment, those variables stay in place.

Co-occurring conditions that haven’t been treated together. Trauma history, substance use, anxiety, ADHD, complex bereavement — these often coexist with treatment-resistant depression and require integrated care that outpatient settings can’t always provide.

What Residential Care Adds

Residential mental health treatment for depression isn’t outpatient with more hours. It’s a different clinical model designed around exactly the variables outpatient can’t address.

Continuous clinical attention. Multiple therapeutic touchpoints per day rather than per week. The depression doesn’t get to settle in between sessions; the work is ongoing.

Accelerated medication trials. With daily psychiatric availability, medication adjustments can happen more responsively. What might take 6 months outpatient often takes 4–6 weeks in a residential setting.

A different environment. Removing the person from the home and routine that have been holding the depression in place creates the conditions for the clinical work to actually take. The benefit isn’t in the location per se — it’s in the interruption of patterns.

Integrated co-occurring care. Trauma work, anxiety treatment, substance use evaluation — all happening as part of the same plan with the same team, rather than as separate referrals that may or may not coordinate.

Group community. The therapeutic value of being among other people who are working through similar things is consistently one of the most-mentioned elements of residential treatment in client feedback. The isolation that depression produces gets interrupted.

How to Know If Residential Is the Right Next Step

Some specific signals worth taking seriously:

  • Two or more failed medication trials with persistent functional impairment
  • Daily life is meaningfully affected — work, relationships, self-care, the ability to enjoy anything
  • Recurring suicidal ideation, even without active planning
  • Cycling between outpatient stability and acute crises (ER visits, brief hospitalizations)
  • A sense, even before any clinician has named it, that what you’re doing isn’t working and you’re running out of options
  • Co-occurring conditions that haven’t been treated together

Any one of those on its own may not be a reason to escalate. The combination, especially over months rather than weeks, is information worth taking seriously.

What the First Conversation Looks Like

A first call to a residential mental health program isn’t an admission. It’s a clinical conversation where someone trained in admissions listens to the situation, asks structured questions, and gives honest input on whether residential is the right level of care — or whether something else (PHP, intensive outpatient with stronger psychiatric coverage, a specific kind of specialist) fits better.

The point of the first call is to make the next decision well, not to commit to anything. Many people take the call and then take a few days to think before deciding.

If You’re Considering Residential Care for Depression

At Bodhi Mental Health, our residential program is structured for situations exactly like the ones described above — depression that hasn’t responded to multiple outpatient courses, often with co-occurring trauma, anxiety, or substance use that hasn’t been addressed in an integrated way.

If you’d like a confidential conversation about whether residential care is right for you or someone you love, call our team at 877-883-0780 or reach out online. The first call is free and we’ll give you honest input on what level of care your situation actually calls for.

If you or someone you love needs help right now, call our team directly at 877-883-0780 — we’re here to talk.

What the Research Shows About Treatment-Resistant Depression and Residential Care

Major depressive disorder affects roughly 21 million U.S. adults each year, and approximately one-third of those individuals do not achieve remission with first-line antidepressant therapy — the clinical definition of treatment-resistant depression (NIMH: Major Depression Statistics). When two or more adequately dosed medication trials and standard psychotherapy have not produced meaningful improvement, the next clinical step is typically a higher level of care that combines pharmacologic reassessment, evidence-based therapy, and structured daily living.

Residential treatment is well positioned to address this clinical picture. A peer-reviewed analysis indexed through the National Library of Medicine found that integrated, multimodal care — including medication optimization, CBT, behavioral activation, and family involvement — produces measurable improvement for individuals with severe and persistent depression who have not responded to outpatient care alone (PMC: Treatment-resistant depression review). Crucially, residential settings allow clinicians to evaluate medication response in real time, address sleep and nutrition, and reduce the daily stressors that often perpetuate depressive episodes.

The American Psychiatric Association also notes that treatment-resistant depression frequently coexists with anxiety, trauma history, or substance-related concerns, and that addressing these together — rather than sequentially — produces better long-term outcomes (APA: What Is Depression?). At Bodhi Mental Health, our residential clinicians coordinate prescriber care, individual therapy, and group programming so that each element reinforces the others.

If depression has not responded to outpatient treatment, a residential level of care may be the appropriate next step. Learn more about our residential program, explore treatment programs, or verify insurance. You can apply now or call 877-883-0780 to speak with admissions.

This article is informational only and is not a substitute for individualized clinical advice. Please consult a qualified mental health clinician for diagnosis and treatment decisions.

/by

Treatment for High Functioning Depression

,
Treatment for High Functioning Depression

Table of Contents

Not everyone with depression shows it on the outside. Some people experience a form of “high functioning” depression, which is more internal than external, more hidden than visible. Thankfully, there is effective treatment for high functioning depression.

What is High Functioning Depression?

Most of us are aware of what depression looks and feels like, at least to some extent. When we think of depression we visualize someone who is sad, withdrawn, and not interested in their usual activities anymore.

However, depression is a complex mental health condition that presents in a variety of different ways. One of these ways is referred to as “high functioning” depression. This term describes someone with depression who can still function at work, school, or parenting.

Persistent Depressive Disorder

High functioning depression is not yet recognized as a clinical diagnosis in the DSM-5. Even so, mental health professionals liken this type of depression to persistent depressive disorder (PDD), also called dysthymia.

PDD refers to a form of depression with less severe symptoms, compared to major depressive disorder. PDD is called persistent because it can linger for two years or longer.

Another term that comes up when attempting to define high functioning depression is “smiling depression.” This describes the person struggling with symptoms of depression as being able to present a false sense of wellbeing. They can put a smile on their face that masks how they are really feeling inside. They are able to function at their jobs or in social settings and appear fine while actually battling depression.

What Causes High Functioning Depression?

Some of the same issues that cause regular forms of clinical depression can also be a trigger for high functioning depression. These possible causes include:

  • A family history of depression
  • A history of trauma
  • Chronic levels of high stress at work, home, or school
  • Having financial problems
  • Dealing with a serious health setback or injury
  • Relationship conflicts at home or work
  • Living in an unsafe environment
  • A health condition or side effects from a medication
  • Substance abuse

Key Signs of High Functioning Depression

It is said that high functioning depression is like a mild form of PDD. This type of depression isn’t debilitating, but does impact quality of life. Some signs you might be dealing with high functioning depression include:

  • Feeling sad or empty
  • Fatigue or lack of energy
  • Low self-esteem
  • Changes in eating habits
  • Sleep problems
  • Feeling hopeless
  • Avoiding social activities
  • Trouble making decisions
  • Feelings of guilt or shame about the past
  • Being impatient or angry
  • Loss of interest in usual daily activities

If you are struggling with ongoing, chronic symptoms of PDD you may think you have no option but to accept it. However, there is treatment for high functioning depression that can offer you some much-needed support. Keep reading.

How Does Living with High Functioning Depression Impact Someone’s Life?

Someone with mild PDD or high functioning depression often hides their condition. Instead of acknowledging the problem, they push through and put on a positive front. This may help them avoid attention about their mental health status, but it never gets them the treatment for high functioning depression they need.

There are various reasons why a person with this type of depression might try to hide it from others. Some of these include:

  • They simply want to keep their mental health issues private
  • They don’t want to become a burden to family members, friends, or coworkers
  • They don’t want to appear weak to others
  • They want to avoid attention
  • They are in denial about how depression is affecting their life

Living with high functioning depression often leads to social withdrawal and isolation. This is because the person would rather be alone than to have to fake it in public or with friends. Also, the condition causes fatigue and sleep problems, so they don’t have the energy to even be social.

Holistic Therapies that Help High Functioning Depression

When you battle depression, self-care and healthy lifestyle habits can go a long way toward improving your daily quality of life. Consider adding these actions to your weekly routine to improve your mood state:

  • Holistic self-care. Holistic methods can improve your overall mood by inducing a state of relaxation. These activities might include mindfulness meditation, yoga, massage therapy, or focused breath work.
  • Nutrition. Adding certain foods to you diet can be helpful for someone with depression. These include leafy greens, avocados, turkey, walnuts, betties, fish and whole grains. Also, moderate the intake of sugary foods, alcohol, and caffeine.
  • Exercise. Regular exercise benefits both physical and mental health. Exercise causes the release of endorphins and also produces serotonin and dopamine. All of these brain chemicals provide immense mental benefits, such as reducing stress, boosting mood, and improving sleep quality.

Comprehensive Depression Treatment

When the above methods do not result in any real improvements in your mental state, there are some treatment options to consider. Treatment for depression is available in three types of settings: private practice, outpatient programs, and residential treatment.

The good news is there is treatment for high functioning depression. For someone with this type of depression, the purpose of seeking treatment is to improve your quality of life. The three pillars of depression treatment include:

  • Medication. Antidepressants may be helpful for some patients with PDD. SSRIs can take 4-6 weeks to reduce depression symptoms. If there is no result after six weeks, the doctor can trial a different drug.
  • Psychotherapy. Working with a therapist can help you work through any underlying emotional issues that may be factors in the depression. Cognitive behavioral therapy can guide you away from negative thoughts and help to restore a sense of control.
  • Group support. Support groups are a safe setting in which to discuss your depression with others who may have a similar condition.

Your secret struggle with PDD can be put behind you with high quality mental health treatment. Do not hesitate to seek the help you deserve.

Bodhi Mental Health Provides Treatment for High Functioning Depression

Bodhi Mental Health is an outpatient mental health program offering all levels of outpatient treatment. We can also guide you toward a leading residential treatment program that limits patient load to just six beds. Let us help you overcome this lingering form of depression. Reach out to the Bodhi team today at (877) 503-0638.

What Clinicians Know About High-Functioning Depression

“High-functioning depression” is not a formal DSM-5 diagnosis, but it describes a recognizable clinical pattern: persistent depressive symptoms that meet criteria for major depressive disorder or persistent depressive disorder (dysthymia) in a person who continues to perform at work, school, or home. The National Institute of Mental Health estimates that major depression affects roughly 8.4% of U.S. adults annually, and a substantial portion of those individuals never seek treatment because outward functioning masks internal suffering (NIMH: Depression).

Peer-reviewed research published through the National Library of Medicine indicates that persistent depressive disorder — particularly when it has lasted two years or more — is associated with greater functional impairment over time, higher rates of co-occurring anxiety, and reduced response to brief treatment interventions than episodic major depression (PMC: Persistent depressive disorder review). Evidence-based treatments include Cognitive Behavioral Therapy (CBT), interpersonal therapy, behavioral activation, and antidepressant medication coordinated with a prescribing psychiatrist.

The American Psychiatric Association also emphasizes that long-standing, lower-grade depression often responds best to combined treatment — medication plus psychotherapy — and that delayed care can deepen the condition over years (APA: What Is Depression?). For people who have been “managing” for years and are now experiencing burnout, suicidal thoughts, or a sense that outpatient therapy is not enough, a residential level of care can offer the time and structure to fully address what has been carried for too long.

If high-functioning depression has begun to erode your daily life, support is available. Learn more about our residential program, explore treatment programs, or verify insurance. You can apply now or call 877-883-0780.

This article is informational only and is not a substitute for individualized clinical advice. Please consult a qualified mental health clinician for diagnosis and treatment decisions.

/by